A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects

Trial Profile

A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2014

At a glance

  • Drugs Beta lapachone (Primary)
  • Indications Macular degeneration; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2014 Results from the multiple dose groups presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 17 Jul 2012 Actual initiation date changed from Sep 2011 to April 2011 as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Actual end date (Apr 2012 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top